2013 Herbert and Maxine Block Memorial Lectureship Award Recipient
Congratulations to Eric S. Lander, PhD, on becoming the 20th recipient of the Herbert and Maxine Block Memorial Lectureship Award for Distinguished Achievement in Cancer.
Dr. Lander is president and founding director of the Broad Institute of Harvard and MIT, a new kind of collaborative biomedical research institution focused on genomic medicine. Founded in 2003, the institute spans Harvard University, the Massachusetts Institute of Technology and the Harvard-affiliated hospitals.
Dr. Lander also is a professor of biology at MIT and of systems biology at Harvard Medical School.
A geneticist, molecular biologist and mathematician, Dr. Lander has played a pioneering role in all aspects of the reading, understanding and medical application of the human genome. He was a principal leader of the international Human Genome Project from 1990 to 2003. In the 1980s, he conceived genomic methods that have made it possible to discover thousands of genes underlying common human diseases, including cancer and diabetes.
In 2008, President Obama appointed Dr. Lander co-chairman of the President’s Council of Advisors on Science and Technology, a group of 21 leading scientists and engineers that advises the White House on matters of health, manufacturing, energy policy, information technology, drug innovation, spectrum and communications policy, nanotechnology and national security.
Previous Award Recipients
(Note: affiliations listed were those held at time of award.)
- Samuel Broder, MD, director of the National Cancer Institute
- Robert C. Young, MD, president, Fox Chase Cancer Center (Philadelphia)
- Bert Vogelstein, MD, professor of Oncology and Molecular Biology/Genetics, Johns Hopkins University School of Medicine (Baltimore)
- Judah Folkman, MD, Andrus Professor of Pediatric Surgery, Harvard Medical School, Children’s Hospital (Boston)
- V. Craig Jordan, PhD, DSc, professor of Pharmacology and director of the Breast Cancer Research Program at the Robert H. Lurie Cancer Center, Northwestern University Medical Center (Chicago)
- Barbara K. Rimer, DrPH, director, Division of Cancer Control and Population Science, National Cancer Institute
- Richard D. Klausner, MD, director of the National Cancer Institute
- John Potter, MD, PhD, director of the Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center (Seattle)
- Donald Coffey, PhD, professor of Urology, Oncology, Pathology, Pharmacology and Molecular Science, Johns Hopkins University School of Medicine (Baltimore)
- David Botstein, PhD, professor and chair, Department of Genetics, Stanford University School of Medicine (Palo Alto, California)
- Daniel Von Hoff, MD, professor of Medicine, Molecular and Cellular Biology, and Pathology; director, Arizona Cancer Center, University of Arizona (Tucson)
- Carlo Croce, MD, director of the Kimmel Cancer Institute/Kimmel Cancer Center at Jefferson Medical College, Thomas Jefferson University (Philadelphia); subsequently joined Ohio State where he serves as director of the Human Cancer Genetics Program
- Larry Norton, MD, medical oncologist leader of the Breast Disease Management Team at Memorial Sloan-Kettering Cancer Center (New York)
- C. Norman Coleman, MD, director, Radiation Oncology Services Program, National Cancer Institute
- Steven Rosenberg, MD, PhD, chief of Surgery, National Cancer Institute; professor of Surgery, George Washington University School of Medicine and Health Sciences
- George Klein, MD, PhD, professor emeritus and research group leader, Microbiology and Tumor Biology Center, Karolinska Institute (Stockholm, Sweden)
- Kathleen M. Foley, MD, attending neurologist, Pain and Palliative Care Service, Memorial Sloan-Kettering Cancer Center; professor, Neurology, Neuroscience and Clinical Pharmacology, Weill Medical College, Cornell University (New York)
- Bruce A. Chabner, MD, professor, Department of Medicine, Harvard Medical School; director, clinical research, Massachusetts General Hospital
- Levi Garraway, MD, PhD, associate professor, Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School